Monthly gift for cancer patients – The Institute of Cancer Research,
At the ICR, we are committed to improving the lives of cancer patients. Yet these discoveries take time and are only possible with continued support from you.
At the ICR, we are committed to improving the lives of cancer patients. Yet these discoveries take time and are only possible with continued support from you.
The panel discusses the lenvatinib plus everolimus regimen for patients with advanced renal cell carcinoma, highlighting clinical trial data on its efficacy and safety profile.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Rohan Garje, MD, discusses considerations when choosing between FDA-approved PARP inhibitor–based combinations for patients with mCRPC.
SEER*Explorer provides access to SEER cancer statistics and detailed statistics for a cancer site by gender, race, calendar year, age, and for a selected number…
The findings of this cohort study suggest that approximately two-thirds of patients with aUC did not receive second-line treatment. Most first-line treatments do not include…
Premal Thaker, MD, MS, discusses how the RAMP-201 trial paved a way for the RAMP-301 trial of avutometinib/defactinib in low-grade serous ovarian cancer.
Although scientific progress in HSCT is ongoing, gaps remain in both access to care and outcomes. An Education Session will review the latest research on…
No significant difference in time to treatment was found between White and Black patients with bladder cancer, but there remained a difference in treatment outcomes.